NSAIDs are anti-infl ammatory, analgesic, and antipyretic agents, and they are typically used chronically to reduce pain, decrease stiff ness, and improve function in patients with osteoarthritis, rheumatoid arthritis, and other forms of arthritis. Additionally, NSAIDs are also used for the more acute treatment of pain including headache, dysmenorrhea, and postoperative pain [1-4]. However, NSAID use conveys potential signifi cant adverse events that include gastrointestinal ulcers with consequential bleeding, perforation or obstruction, renal dysfunction and consequent renal failure, cardiovascular events, as well as the risk for death [5] [6] [7] [8] [9] [10] [11] . Despite the many available forms of NSAIDs, including injectable as well as topical, oral dosing is the most common route, usually the one route consistently associated with chronic use and thus the one that carries the most risk. In the last several years, several topical NSAIDs including either diclofenac ibuprofen or salicylates for chronic pain have been approved in the United States while similar drugs have been available in Europe for years. One study of a diclofenac topical liquid included an oral diclofenac comparator, and demonstrated no diff erence in effi cacy between the two therapies in treatment for the pain of osteoarthritis in the knee [12] .
Th e risk for potential gastrointestinal damage due to systemic exposure of NSAIDs is well defi ned, including gastrointestinal symptoms such as dyspepsia and abdominal pain, increased incidence of endoscopic ulcers, bleeding, and death. A history of prior gastrointestinal symptoms or bleed ing, the presence of other risk factors such as advanc ing age, higher doses of NSAID, duration of NSAID use, as well as the frailty of the patient all increase the risk for upper gastrointestinal damage and conse quent bleeding [13] . Use of NSAIDs with a longer half-life probably places patients at greater risk of adverse events.
Strategies to decrease the risk for damage to the gastrointestinal tract have included the transition to other types of drugs, use of lower dose systemic NSAIDs, and the use of topical NSAIDs, but there are still patients who require more chronic exposure to higher dose therapy. In addition, other strategies include the addition of prostaglandin analogues, H 2 receptor antagonists, or proton pump inhibitors as concomitant therapies [14] [15] [16] [17] [18] . More recently, combination products have been developed [19, 20] . Th is supplement will review the continued importance of NSAIDs as part of a strategy to continue to treat pain adequately as well as the attempts to mitigate the risks associated with the use of these drugs.
Abbreviations NSAID, nonsteroidal anti-infl ammatory drug.
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